1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Hemostemix Inc.
  6. News
  7. Summary
    HEM   CA4236943060

HEMOSTEMIX INC.

(HEM)
Delayed Bourse de Toronto  -  05/20 03:52:20 pm EDT
0.3300 CAD   -5.71%
05/20Hemostemix Reports Non-Brokered Private Placement; Down 8.6%
MT
05/19Hemostemix Inc. announced a financing transaction
CI
05/03Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hemostemix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

11/29/2021 | 12:13pm EDT

Hemostemix Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was CAD 1.04 million compared to CAD 1.61 million a year ago. For the nine months, net loss was CAD 3.07 million compared to CAD 3.78 million a year ago.


© S&P Capital IQ 2021
All news about HEMOSTEMIX INC.
05/20Hemostemix Reports Non-Brokered Private Placement; Down 8.6%
MT
05/19Hemostemix Inc. announced a financing transaction
CI
05/03Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
05/03Hemostemix Inc. Auditor Raises 'Going Concern' Doubt
CI
04/25Hemostemix Closes $2.75 Million Debenture Offering
MT
04/25Hemostemix Inc. announced that it has received CAD 2.75 million in funding
CI
03/02Hemostemix Up 5.7% after Reporting Private Placement of Convertible Debentures
MT
03/02Hemostemix Inc. announced that it expects to receive CAD 2.75 million in funding
CI
02/28Hemostemix Inc. announced that it has received CAD 1.20485 million in funding
CI
02/03HEMOSTEMIX : Announces Financing
PU
More news
Financials
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 22,5 M 17,5 M 17,5 M
EV / Sales -1
EV / Sales 0
Nbr of Employees -
Free-Float 85,3%
Chart HEMOSTEMIX INC.
Duration : Period :
Hemostemix Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Thomas A. Smeenk President, Chief Executive Officer & Director
Christina Wu Chief Financial Officer
Peter Alan Lacey Chairman
Fraser C. Henderson Chief Medical Officer
Peter Pavlin Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
HEMOSTEMIX INC.106.25%18
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612